Nilotinib treatment-associated accelerated atherosclerosis: when is the risk justified?
Gespeichert in:
| Veröffentlicht in: | Leukemia 2013-09, Vol.27 (9), p.1939-1940 |
|---|---|
| 1. Verfasser: | |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1940 |
|---|---|
| container_issue | 9 |
| container_start_page | 1939 |
| container_title | Leukemia |
| container_volume | 27 |
| creator | Tefferi, A |
| description | |
| doi_str_mv | 10.1038/leu.2013.112 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_3768111</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A345610707</galeid><sourcerecordid>A345610707</sourcerecordid><originalsourceid>FETCH-LOGICAL-c548t-a9b7b1afcee3c9fcbbd7cca3067e2f8e11e870025561b6b13401c216d6da50f33</originalsourceid><addsrcrecordid>eNptkt-L1DAQx4Mo3nr65rMUBJ_smknapPVBOQ5_waEvio8hTafbrG1yl6Qe99-bZc9lF45AEmY-883MZAh5CXQNlDfvJlzWjAJfA7BHZAWVFGVd1_CYrGjTyFK0rDojz2LcUrpziqfkjHFBK8bpivz-biefrLNdkQLqNKNLpY7RG6sT9oU2BicM-3saMfhopt1u4_vidkRX2FhkexFs_FNsl5jsYLH_-Jw8GfQU8cX9eU5-ff708_JrefXjy7fLi6vS1FWTX2o72YEeDCI37WC6rpfGaE6FRDY0CICNpJTVtYBOdMArCoaB6EWvazpwfk4-7HWvl27G3uT0g57UdbCzDnfKa6tOPc6OauP_Ki5FAwBZ4PW9QPA3C8aktn4JLuesoGKtkC3LbT5QGz2hsm7wWczMNhp1waucHJVUZmr9AJVXj7M13uFgs_0k4M1RwIh6SmP005Ksd_EUfLsHTW59DDgcKgSqdmOg8hio3RioPAYZf3XclQP8_98zUO6BmF1ug-Go6ocE_wEc5bzl</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1429679210</pqid></control><display><type>article</type><title>Nilotinib treatment-associated accelerated atherosclerosis: when is the risk justified?</title><source>MEDLINE</source><source>Nature</source><source>EZB-FREE-00999 freely available EZB journals</source><source>Alma/SFX Local Collection</source><creator>Tefferi, A</creator><creatorcontrib>Tefferi, A</creatorcontrib><identifier>ISSN: 0887-6924</identifier><identifier>EISSN: 1476-5551</identifier><identifier>DOI: 10.1038/leu.2013.112</identifier><identifier>PMID: 23604230</identifier><language>eng</language><publisher>London: Nature Publishing Group UK</publisher><subject>692/699/67/1059/99 ; 692/699/67/1990/283/1896 ; 692/699/75/593/2100 ; 692/700/565/2194 ; Antineoplastic Agents - adverse effects ; Arterial Occlusive Diseases - complications ; Atherosclerosis ; Benzamides - adverse effects ; Cancer Research ; Cardiovascular disease ; Complications and side effects ; Critical Care Medicine ; Dosage and administration ; Heart attacks ; Hematology ; Humans ; Intensive ; Internal Medicine ; Kinases ; Letter to the Editor ; Letters to the editor ; Leukemia ; Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy ; Medicine ; Medicine & Public Health ; Nilotinib ; Oncology ; Peripheral Arterial Disease - complications ; Piperazines - adverse effects ; Pyrimidines - adverse effects ; Remission (Medicine) ; Risk factors</subject><ispartof>Leukemia, 2013-09, Vol.27 (9), p.1939-1940</ispartof><rights>The Author(s) 2013</rights><rights>COPYRIGHT 2013 Nature Publishing Group</rights><rights>Copyright Nature Publishing Group Sep 2013</rights><rights>Copyright © 2013 Macmillan Publishers Limited 2013 Macmillan Publishers Limited</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c548t-a9b7b1afcee3c9fcbbd7cca3067e2f8e11e870025561b6b13401c216d6da50f33</citedby><cites>FETCH-LOGICAL-c548t-a9b7b1afcee3c9fcbbd7cca3067e2f8e11e870025561b6b13401c216d6da50f33</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,314,780,784,885,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/23604230$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Tefferi, A</creatorcontrib><title>Nilotinib treatment-associated accelerated atherosclerosis: when is the risk justified?</title><title>Leukemia</title><addtitle>Leukemia</addtitle><addtitle>Leukemia</addtitle><subject>692/699/67/1059/99</subject><subject>692/699/67/1990/283/1896</subject><subject>692/699/75/593/2100</subject><subject>692/700/565/2194</subject><subject>Antineoplastic Agents - adverse effects</subject><subject>Arterial Occlusive Diseases - complications</subject><subject>Atherosclerosis</subject><subject>Benzamides - adverse effects</subject><subject>Cancer Research</subject><subject>Cardiovascular disease</subject><subject>Complications and side effects</subject><subject>Critical Care Medicine</subject><subject>Dosage and administration</subject><subject>Heart attacks</subject><subject>Hematology</subject><subject>Humans</subject><subject>Intensive</subject><subject>Internal Medicine</subject><subject>Kinases</subject><subject>Letter to the Editor</subject><subject>Letters to the editor</subject><subject>Leukemia</subject><subject>Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Nilotinib</subject><subject>Oncology</subject><subject>Peripheral Arterial Disease - complications</subject><subject>Piperazines - adverse effects</subject><subject>Pyrimidines - adverse effects</subject><subject>Remission (Medicine)</subject><subject>Risk factors</subject><issn>0887-6924</issn><issn>1476-5551</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2013</creationdate><recordtype>article</recordtype><sourceid>C6C</sourceid><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><recordid>eNptkt-L1DAQx4Mo3nr65rMUBJ_smknapPVBOQ5_waEvio8hTafbrG1yl6Qe99-bZc9lF45AEmY-883MZAh5CXQNlDfvJlzWjAJfA7BHZAWVFGVd1_CYrGjTyFK0rDojz2LcUrpziqfkjHFBK8bpivz-biefrLNdkQLqNKNLpY7RG6sT9oU2BicM-3saMfhopt1u4_vidkRX2FhkexFs_FNsl5jsYLH_-Jw8GfQU8cX9eU5-ff708_JrefXjy7fLi6vS1FWTX2o72YEeDCI37WC6rpfGaE6FRDY0CICNpJTVtYBOdMArCoaB6EWvazpwfk4-7HWvl27G3uT0g57UdbCzDnfKa6tOPc6OauP_Ki5FAwBZ4PW9QPA3C8aktn4JLuesoGKtkC3LbT5QGz2hsm7wWczMNhp1waucHJVUZmr9AJVXj7M13uFgs_0k4M1RwIh6SmP005Ksd_EUfLsHTW59DDgcKgSqdmOg8hio3RioPAYZf3XclQP8_98zUO6BmF1ug-Go6ocE_wEc5bzl</recordid><startdate>20130901</startdate><enddate>20130901</enddate><creator>Tefferi, A</creator><general>Nature Publishing Group UK</general><general>Nature Publishing Group</general><scope>C6C</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QL</scope><scope>7RV</scope><scope>7T5</scope><scope>7T7</scope><scope>7TM</scope><scope>7TO</scope><scope>7U9</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FD</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>C1K</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>KB0</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M7N</scope><scope>M7P</scope><scope>NAPCQ</scope><scope>P64</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>5PM</scope></search><sort><creationdate>20130901</creationdate><title>Nilotinib treatment-associated accelerated atherosclerosis: when is the risk justified?</title><author>Tefferi, A</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c548t-a9b7b1afcee3c9fcbbd7cca3067e2f8e11e870025561b6b13401c216d6da50f33</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2013</creationdate><topic>692/699/67/1059/99</topic><topic>692/699/67/1990/283/1896</topic><topic>692/699/75/593/2100</topic><topic>692/700/565/2194</topic><topic>Antineoplastic Agents - adverse effects</topic><topic>Arterial Occlusive Diseases - complications</topic><topic>Atherosclerosis</topic><topic>Benzamides - adverse effects</topic><topic>Cancer Research</topic><topic>Cardiovascular disease</topic><topic>Complications and side effects</topic><topic>Critical Care Medicine</topic><topic>Dosage and administration</topic><topic>Heart attacks</topic><topic>Hematology</topic><topic>Humans</topic><topic>Intensive</topic><topic>Internal Medicine</topic><topic>Kinases</topic><topic>Letter to the Editor</topic><topic>Letters to the editor</topic><topic>Leukemia</topic><topic>Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Nilotinib</topic><topic>Oncology</topic><topic>Peripheral Arterial Disease - complications</topic><topic>Piperazines - adverse effects</topic><topic>Pyrimidines - adverse effects</topic><topic>Remission (Medicine)</topic><topic>Risk factors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Tefferi, A</creatorcontrib><collection>Springer Nature OA Free Journals</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Proquest Nursing & Allied Health Source</collection><collection>Immunology Abstracts</collection><collection>Industrial and Applied Microbiology Abstracts (Microbiology A)</collection><collection>Nucleic Acids Abstracts</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>Technology Research Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biological Science Database</collection><collection>Nursing & Allied Health Premium</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Leukemia</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Tefferi, A</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Nilotinib treatment-associated accelerated atherosclerosis: when is the risk justified?</atitle><jtitle>Leukemia</jtitle><stitle>Leukemia</stitle><addtitle>Leukemia</addtitle><date>2013-09-01</date><risdate>2013</risdate><volume>27</volume><issue>9</issue><spage>1939</spage><epage>1940</epage><pages>1939-1940</pages><issn>0887-6924</issn><eissn>1476-5551</eissn><cop>London</cop><pub>Nature Publishing Group UK</pub><pmid>23604230</pmid><doi>10.1038/leu.2013.112</doi><tpages>2</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0887-6924 |
| ispartof | Leukemia, 2013-09, Vol.27 (9), p.1939-1940 |
| issn | 0887-6924 1476-5551 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_3768111 |
| source | MEDLINE; Nature; EZB-FREE-00999 freely available EZB journals; Alma/SFX Local Collection |
| subjects | 692/699/67/1059/99 692/699/67/1990/283/1896 692/699/75/593/2100 692/700/565/2194 Antineoplastic Agents - adverse effects Arterial Occlusive Diseases - complications Atherosclerosis Benzamides - adverse effects Cancer Research Cardiovascular disease Complications and side effects Critical Care Medicine Dosage and administration Heart attacks Hematology Humans Intensive Internal Medicine Kinases Letter to the Editor Letters to the editor Leukemia Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy Medicine Medicine & Public Health Nilotinib Oncology Peripheral Arterial Disease - complications Piperazines - adverse effects Pyrimidines - adverse effects Remission (Medicine) Risk factors |
| title | Nilotinib treatment-associated accelerated atherosclerosis: when is the risk justified? |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-27T16%3A44%3A02IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Nilotinib%20treatment-associated%20accelerated%20atherosclerosis:%20when%20is%20the%20risk%20justified?&rft.jtitle=Leukemia&rft.au=Tefferi,%20A&rft.date=2013-09-01&rft.volume=27&rft.issue=9&rft.spage=1939&rft.epage=1940&rft.pages=1939-1940&rft.issn=0887-6924&rft.eissn=1476-5551&rft_id=info:doi/10.1038/leu.2013.112&rft_dat=%3Cgale_pubme%3EA345610707%3C/gale_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1429679210&rft_id=info:pmid/23604230&rft_galeid=A345610707&rfr_iscdi=true |